One Down, Two To Go For Adcetris’ Expansion In Lymphoma
Takeda/Seattle Genetics announced positive Phase III data from the ALCANZA trial evaluating the antibody drug-conjugate in patients with cutaneous T-cell lymphoma (CTCL). Phase III studies in other potentially larger lymphoma indications are ongoing.
You may also be interested in...
Mogamulizumab has met its primary survival endpoint in a comparative Phase III trial in cutaneous T-cell lymphoma, positioning the Kyowa Hakko Kirin product as a potential close follower to Adcetris in the second-line setting.
Regarding FDA filing in new CTCL indication in 2017, Seattle Genetics is hoping for a label that covers all patients, regardless of positivity for CD30, though the Phase III ALCANZA study was done in biomarker expressers.
The latest drug development news and highlights from our FDA Performance Tracker.